Escitalopram Ameliorates Cardiomyopathy in Type 2 Diabetic Rats Via Modulation of Receptor for Advanced Glycation End Products and Its Downstream Signaling Cascades

Overview

Journal Front Pharmacol

Date 2021 Jan 1

PMID 33384599

Citations 2

Authors

Lamiaa A Ahmed

Nesma A Shiha

Amina S Attia

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes mellitus (T2DM) has been recognized as a known risk factor for cardiovascular diseases. Additionally, studies have shown the prevalence of depression among people with diabetes. Thus, the current study aimed to investigate the possible beneficial effects of escitalopram, a selective serotonin reuptake inhibitor, on metabolic changes and cardiac complications in type 2 diabetic rats. Diabetes was induced by feeding the rats high fat-high fructose diet (HFFD) for 8 weeks followed by a subdiabetogenic dose of streptozotocin (STZ) (35 mg/kg, i. p.). Treatment with escitalopram (10 mg/kg/day; p. o.) was then initiated for 4 weeks. At the end of the experiment, electrocardiography was performed and blood samples were collected for determination of glycemic and lipid profiles. Animals were then euthanized and heart samples were collected for biochemical and histopathological examinations. Escitalopram alleviated the HFFD/STZ-induced metabolic and cardiac derangements as evident by improvement of oxidative stress, inflammatory, fibrogenic and apoptotic markers in addition to hypertrophy and impaired conduction. These results could be secondary to its beneficial effects on the glycemic control and hence the reduction of receptor for advanced glycation end products content as revealed in the present study. In conclusion, escitalopram could be considered a favorable antidepressant medication in diabetic patients as it seems to positively impact the glycemic control in diabetes in addition to prevention of its associated cardiovascular complications.

Citing Articles

The Protective Effect of Theaflavins on the Kidney of Mice with Type II Diabetes Mellitus.

Wang J, Jiang J, Zhao C, Shan H, Shao Z, Wang C Nutrients. 2023; 15(1).

PMID: 36615858 PMC: 9824224. DOI: 10.3390/nu15010201.

The serotonergic system dysfunction in diabetes mellitus.

Cai Y, Li X, Zhou H, Zhou J Front Cell Neurosci. 2022; 16:899069.

PMID: 35910256 PMC: 9331500. DOI: 10.3389/fncel.2022.899069.

References

Bugger H, Abel E . Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014; 57(4):660-71. PMC: 3969857. DOI: 10.1007/s00125-014-3171-6. View

Chang S, Lin J, CHI T, Liu I, Cheng J . An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats. Diabetologia. 1999; 42(2):250-5. DOI: 10.1007/s001250051146. View

Miki T, Yuda S, Kouzu H, Miura T . Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2012; 18(2):149-66. PMC: 3593009. DOI: 10.1007/s10741-012-9313-3. View

Zhang J, Knapton A, Lipshultz S, Weaver J, Herman E . Isoproterenol-induced cardiotoxicity in sprague-dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol Pathol. 2008; 36(2):277-8. DOI: 10.1177/0192623307313010. View

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9. DOI: 10.1007/BF00280883. View

Ibrahim W, Abdelkader N, Ismail H, Khattab M . Escitalopram Ameliorates Cognitive Impairment in D-Galactose-Injected Ovariectomized Rats: Modulation of JNK, GSK-3β, and ERK Signalling Pathways. Sci Rep. 2019; 9(1):10056. PMC: 6624366. DOI: 10.1038/s41598-019-46558-1. View

Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S . Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology. 2007; 149(1):380-8. DOI: 10.1210/en.2007-0877. View

Grisanti L . Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. Front Physiol. 2018; 9:1669. PMC: 6275303. DOI: 10.3389/fphys.2018.01669. View

Wold L, Ceylan-Isik A, Ren J . Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin. 2005; 26(8):908-17. DOI: 10.1111/j.1745-7254.2005.00146.x. View

10.

Psyrogiannis A, Kyriazopoulou V, Symeonidis A, Leotsinidis M, Vagenakis A . Relative iron "overload" in offspring of patients with type 2 diabetes mellitus: a new component in the conundrum of insulin resistance syndrome?. Hormones (Athens). 2006; 2(3):161-8. DOI: 10.14310/horm.2002.1196. View

11.

Guo S, Chen L, Cheng S, Xu H . Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019; 98(22):e15786. PMC: 6708706. DOI: 10.1097/MD.0000000000015786. View

12.

Basciano H, Federico L, Adeli K . Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond). 2005; 2(1):5. PMC: 552336. DOI: 10.1186/1743-7075-2-5. View

13.

Hajduch E, Darakhshan F, Hundal H . Fructose uptake in rat adipocytes: GLUT5 expression and the effects of streptozotocin-induced diabetes. Diabetologia. 1998; 41(7):821-8. DOI: 10.1007/s001250050993. View

14.

Goldin A, Beckman J, Schmidt A, Creager M . Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006; 114(6):597-605. DOI: 10.1161/CIRCULATIONAHA.106.621854. View

15.

Shao C, Rozanski G, Nagai R, Stockdale F, Patel K, Wang M . Carbonylation of myosin heavy chains in rat heart during diabetes. Biochem Pharmacol. 2010; 80(2):205-17. PMC: 2988575. DOI: 10.1016/j.bcp.2010.03.024. View

16.

Elmazar M, El-Abhar H, Schaalan M, Farag N . Phytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations. PLoS One. 2013; 8(1):e45638. PMC: 3534692. DOI: 10.1371/journal.pone.0045638. View

17.

Goodnick P . Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001; 13(1):31-41. DOI: 10.1023/a:1009012815127. View

18.

Lin E, Rutter C, Katon W, Heckbert S, Ciechanowski P, Oliver M . Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care. 2009; 33(2):264-9. PMC: 2809260. DOI: 10.2337/dc09-1068. View

19.

van Noort V, Scholch S, Iskar M, Zeller G, Ostertag K, Schweitzer C . Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res. 2014; 74(20):5690-9. DOI: 10.1158/0008-5472.CAN-13-3540. View

20.

Liu Q, Wang G, Zhou G, Tan Y, Wang X, Wei W . Angiotensin II-induced p53-dependent cardiac apoptotic cell death: its prevention by metallothionein. Toxicol Lett. 2009; 191(2-3):314-20. DOI: 10.1016/j.toxlet.2009.09.015. View